Shares of Smith & Nephew plc (NYSE:SNN) have earned a consensus recommendation of “Hold” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $42.00.

A number of analysts have recently issued reports on the company. Berenberg Bank reaffirmed a “buy” rating on shares of Smith & Nephew in a research report on Monday, May 11th. ValuEngine raised Smith & Nephew from a “sell” rating to a “hold” rating in a research report on Thursday, March 5th. Citigroup cut Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 14th. Morgan Stanley raised Smith & Nephew from an “equal weight” rating to an “overweight” rating in a research report on Thursday, June 4th. Finally, BNP Paribas cut Smith & Nephew from a “neutral” rating to an “underperform” rating in a research report on Friday, June 5th.

Shares of SNN traded up $0.27 during mid-day trading on Tuesday, reaching $37.89. The company’s stock had a trading volume of 386,300 shares, compared to its average volume of 783,439. Smith & Nephew has a 1-year low of $26.07 and a 1-year high of $52.26. The stock has a market cap of $16.47 billion, a P/E ratio of 18.57, a PEG ratio of 6.06 and a beta of 0.58. The business has a 50-day simple moving average of $40.58 and a two-hundred day simple moving average of $42.72. The company has a current ratio of 2.06, a quick ratio of 1.03 and a debt-to-equity ratio of 0.38.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada increased its stake in shares of Smith & Nephew by 101.6% during the first quarter. Royal Bank of Canada now owns 720,405 shares of the medical equipment provider’s stock worth $25,841,000 after purchasing an additional 363,007 shares during the period. Coldstream Capital Management Inc. increased its stake in shares of Smith & Nephew by 39.2% during the first quarter. Coldstream Capital Management Inc. now owns 11,855 shares of the medical equipment provider’s stock worth $425,000 after purchasing an additional 3,340 shares during the period. Morgan Stanley increased its stake in shares of Smith & Nephew by 111.4% during the first quarter. Morgan Stanley now owns 237,551 shares of the medical equipment provider’s stock worth $8,520,000 after purchasing an additional 125,182 shares during the period. FDx Advisors Inc. increased its stake in shares of Smith & Nephew by 18.7% during the first quarter. FDx Advisors Inc. now owns 30,102 shares of the medical equipment provider’s stock worth $1,080,000 after purchasing an additional 4,735 shares during the period. Finally, Equitable Trust Co. increased its stake in shares of Smith & Nephew by 57.6% during the first quarter. Equitable Trust Co. now owns 128,969 shares of the medical equipment provider’s stock worth $4,626,000 after purchasing an additional 47,123 shares during the period. Institutional investors own 9.45% of the company’s stock.

About Smith & Nephew

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Featured Story: What is Blockchain?

Analyst Recommendations for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.